DNA合成市場：機会分析と業界予測、2026-2035年

世界のDNA合成市場規模は、2025年には57億ドルと評価され、2035年には304億ドルに達すると予測されています。2026年から2035年にかけての年平均成長率（CAGR）は18.2%です。DNA合成とは、化学的または酵素的手法を用いてDNA分子を人工的に合成する技術であり、研究者は幅広い用途向けにカスタマイズされたDNA配列を設計、組み立て、製造することができます。DNA合成は、現代のバイオテクノロジー、分子生物学、合成生物学、創薬、遺伝子工学において重要な役割を果たしています。

DNA合成技術には、オリゴヌクレオチド合成と遺伝子合成があり、これらによって、短いDNA断片から全長遺伝子までを高精度かつスケーラブルに製造することが可能です。これらの合成DNA配列は、研究、診断、治療薬開発、ワクチン設計、農業バイオテクノロジーなど幅広い分野で活用されており、ライフサイエンス分野におけるイノベーションの基盤となるツールとなっています。

主なポイント：市場動向と洞察

• 北米は2025年までにDNA合成市場を牽引し、最大の市場シェアを獲得する見込みです。
• DNA合成市場は予測期間中に大幅な成長が見込まれます。
• 製品・サービス別に見ると、2025年にはオリゴヌクレオチド分野がDNA合成市場で最大のシェアを占めました。しかし、予測期間中は遺伝子合成分野が最も高いCAGRで成長すると予想されています。
• 用途別に見ると、2025年には研究開発分野が収益面でDNA合成市場で最大のシェアを占めました。治療分野は予測期間中に最も高いCAGRを記録すると予想されています。
• エンドユーザー別に見ると、2025年には製薬・バイオテクノロジー企業分野が収益面でDNA合成市場で最大のシェアを占めました。しかし、予測期間中は学術・研究機関が最も高いCAGRを記録すると予想されています。
• Danaher Corporation、Eurofins Scientific SE、Thermo Fisher Scientific Inc.、Twist Bioscience、GenScript Biotech Corporation、Merck KGaA、Bioneer Corporation、Telesis Bio、Azenta Inc.、味の素バイオファーマは、強力な技術力、グローバルな事業展開、そしてイノベーションへの継続的な投資。これらの企業は、研究、診断、治療用途における高まる需要に応えるため、高品質で拡張性があり、迅速なDNA合成ソリューションを提供することで、合成生物学の発展を牽引しています。

ステークホルダーにとっての主なメリット

• 本レポートは、2025年から2035年までのDNA合成市場の市場セグメント、現在のトレンド、予測、および動向に関する定量分析を提供し、DNA合成市場における主要な機会を特定します。
• 市場調査では、主要な推進要因、阻害要因、および機会に関する情報も提供しています。
• ポーターの5フォース分析は、買い手と供給者の影響力を明らかにし、ステークホルダーが利益重視のビジネス上の意思決定を行い、サプライヤーと買い手のネットワークを強化できるようにします。
• DNA合成市場のセグメンテーションに関する詳細な分析は、市場における主要な機会を特定するのに役立ちます。
• 各地域の主要国は、世界市場への収益貢献度に基づいてマッピングされています。
• 市場プレーヤーの位置付けは、ベンチマークを容易にし、市場プレーヤーの現在の位置を明確に理解するのに役立ちます。
• 本レポートには、地域および世界のDNA合成市場のトレンド、主要プレーヤー、市場セグメント、アプリケーション分野、および市場成長戦略の分析が含まれています。

DNA合成市場の見通しは、製品・サービス、タイプ、用途、エンドユーザー、地域に分類されます。製品・サービスに基づいて、製品とサービスに二分されます。製品はさらに、機器と試薬・消耗品に二分されます。タイプに基づいて、DNA合成市場はオリゴヌクレオチド合成と遺伝子合成に分類されます。アプリケーションに基づいて、DNA合成市場は診断、治療、研究開発に分類されます。エンドユーザーに基づいて、DNA合成市場は製薬・バイオテクノロジー企業、診断企業、学術・研究機関、その他に分類されます。地域別に見ると、市場は北米、ヨーロッパ、アジア太平洋、LAMEA（ラテンアメリカ、中東、アフリカ）で調査されています。

DNA Synthesis Market Research, 2035

The global DNA synthesis market size was valued at $5.7 billion in 2025, and is projected to reach $30.4 billion by 2035, growing at a CAGR of 18.2% from 2026 to 2035. DNA synthesis refers to the artificial creation of DNA molecules through chemical or enzymatic methods, enabling researchers to design, assemble, and produce customized DNA sequences for a wide range of applications. It plays a critical role in modern biotechnology, molecular biology, synthetic biology, drug discovery, and genetic engineering.

DNA synthesis technologies include oligonucleotide synthesis and gene synthesis, which allow the production of short DNA fragments as well as full-length genes with high precision and scalability. These synthesized DNA sequences are widely used in research, diagnostics, therapeutics development, vaccine design, and agricultural biotechnology, making them a foundational tool in life sciences innovation.

Key Takeaways: Market Trends & Insights

• North America dominated the DNA synthesis market with a largest DNA Synthesis Market share in 2025.
• The DNA synthesis market is expected to grow significantly over the forecast period.
• On the basis of product & services, the oligonucleotide segment accounted for the largest DNA synthesis market share in 2025. However, the gene synthesis segment is anticipated to grow at the fastest CAGR during the forecast period
• On the basis of application, the research & development segment accounted for the largest DNA synthesis market share in terms of revenue in 2025. Therapeutics is expected to register the highest CAGR during the forecast period
• On the basis of end user, the pharmaceutical & biotechnology companies segment accounted for the largest DNA synthesis market share in terms of revenue in 2025. However, academic & research institutes are expected to register the highest CAGR during the forecast period
• Danaher Corporation, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Twist Bioscience, GenScript Biotech Corporation, Merck KGaA, Bioneer Corporation, Telesis Bio, Azenta Inc., and Ajinomoto Bio-Pharma, have emerged as prominent players in the DNA synthesis market, driven by their strong technological expertise, global operational footprint, and sustained investments in innovation. These companies are at the forefront of advancing synthetic biology by offering high-quality, scalable, and rapid DNA synthesis solutions to meet the growing demand across research, diagnostics, and therapeutic applications.

Market Dynamics

Drivers

Rising Demand for Genomics and Precision Medicine 

The DNA synthesis market size is primarily driven by the accelerating adoption of genomics-based healthcare and the global shift toward precision medicine. Increasing integration of genomic profiling into clinical decision-making has significantly expanded the demand for synthetic DNA, particularly oligonucleotides, probes, and gene constructs used in diagnostics, biomarker discovery, and therapeutic development. The declining cost of next-generation sequencing has further amplified this trend by generating large-scale genomic datasets that require synthetic DNA for validation, assay development, and functional genomics studies. In oncology, infectious diseases, and rare genetic disorders, DNA synthesis is increasingly utilized in the development of patient-specific diagnostic tools and targeted therapeutic approaches, including personalized cancer vaccines and gene-editing strategies. Pharmaceutical and biotechnology companies are increasingly investing in genomics-enabled drug discovery pipelines, thereby strengthening downstream demand for synthetic DNA inputs. Additionally, government-funded genome initiatives and population-scale sequencing programs are further reinforcing market expansion. As precision medicine continues to transition from research to clinical application, DNA synthesis is expected to remain a critical enabling technology, supporting high-throughput, scalable, and application-specific genetic material production across both research and clinical ecosystems.

Growth in Synthetic Biology and Biopharmaceutical Innovation 

The DNA synthesis market growth of synthetic biology and biopharmaceutical innovation represents a major structural driver. Synthetic biology applications rely extensively on engineered DNA sequences for the design and construction of novel biological systems, enabling advancements in industrial biotechnology, metabolic engineering, and sustainable bio-manufacturing. DNA synthesis is central to the development of recombinant proteins, monoclonal antibodies, vaccines, and next-generation cell and gene therapies. The increasing adoption of mRNA-based therapeutics and vaccines has further strengthened upstream demand for synthetic DNA templates. Moreover, rising investments from venture capital firms in synthetic biology startups have accelerated commercialization of automated gene synthesis platforms, reducing turnaround times and improving accessibility. The transition from traditional cloning methods to de novo gene synthesis is also reshaping R&D workflows, enabling faster design-build-test cycles in biopharmaceutical development. Additionally, applications in agricultural biotechnology, including genetically engineered crops and microbial systems, are expanding the industrial scope of DNA synthesis. As industries increasingly move toward bio-based production systems, synthetic DNA is becoming a foundational input, positioning the market for sustained long-term growth across healthcare, industrial, and environmental biotechnology segments.

Restraints

High Cost and Technical Complexity of Long-Sequence DNA Synthesis

Despite strong growth momentum, the DNA synthesis market is constrained by relatively high costs and technical complexity associated with long-sequence and high-fidelity gene synthesis. While short oligonucleotide synthesis has become increasingly commoditized, the production of long or complex DNA sequences remains resource-intensive due to multi-step assembly, amplification, and error correction requirements. Synthesis errors tend to increase with sequence length, necessitating extensive purification and validation processes that elevate overall production costs and turnaround times. These cost pressures are particularly significant for academic institutions, early-stage biotech firms, and emerging market participants with limited R&D budgets. Additionally, the requirement for specialized infrastructure, automated synthesis platforms, and skilled technical personnel creates a high entry barrier for smaller players. Even with advancements in automation, challenges persist in synthesizing GC-rich regions, repetitive sequences, and highly complex constructs. As a result, cost sensitivity and technical constraints continue to limit broader adoption, particularly in price-sensitive research environments and regions with limited access to advanced biotechnology infrastructures.

Ethical, Regulatory, and Biosecurity Concerns

The DNA synthesis market is also restrained by increasing regulatory scrutiny and biosecurity-related compliance frameworks aimed at mitigating dual-use risks. The ability to synthesize genetic material raises concerns regarding potential misuse in the creation of pathogenic organisms or other harmful biological agents, prompting governments and regulatory agencies to implement stringent oversight mechanisms. Mandatory sequence screening, customer verification protocols, and export control regulations are becoming standard requirements across major markets, increasing operational complexity for service providers. Compliance with these evolving regulatory frameworks often results in longer order processing times and higher administrative costs. Furthermore, ethical considerations surrounding gene editing, synthetic embryos, and germline modification continue to influence policy development and public acceptance of synthetic biology technologies. Variability in regulatory standards across regions adds further complexity for global DNA synthesis providers operating across multiple jurisdictions. Companies are also required to invest in advanced biosecurity screening software and dedicated compliance infrastructure, which increases operational expenditure. Collectively, these regulatory and ethical constraints act as moderating factors on market expansion despite strong underlying demand.

Consumer & Industry Demand – Why is demand increasing in DNA Synthesis market?

The demand in the DNA synthesis market is increasing rapidly due to the expanding role of synthetic biology in modern science and industry. Advances in gene editing technologies such as CRISPR, along with rising applications in personalized medicine, vaccine development, and cell and gene therapies, are significantly driving the need for custom DNA sequences. The growing focus on biologics and mRNA-based therapeutics accelerated after the COVID-19 pandemic has further boosted demand for high-quality, scalable DNA synthesis. In addition, increasing research activities in genomics, drug discovery, and agricultural biotechnology are contributing to market growth, as scientists require precise and rapid DNA constructs for experimentation. Technological innovations by companies such as Twist Bioscience, Thermo Fisher Scientific Inc., and GenScript Biotech Corporation including automation, high-throughput platforms, and cost-effective synthesis methods are making DNA synthesis more accessible and efficient. Furthermore, increasing investments from governments and private sectors in life sciences research, along with the expansion of biotechnology startups, are fueling sustained demand across healthcare, industrial, and environmental applications.

Segmental Analysis

The DNA Synthesis market outlook is segmented into product & services, type, application, end user, and region. On the basis of product & services, it is bifurcated into product and services. The products are further bifurcated into instruments and reagent & consumables. On the basis of type, the DNA synthesis market is segregated into oligonucleotide synthesis and gene synthesis. On the basis of application, the DNA synthesis marketis categorized into diagnostics, therapeutics, research & development. On the basis of end user, the DNA synthesis market is categorized into pharmaceutical & biotechnology companies, diagnostic companies, academic & research institutes, and others. Region-wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA

Which Segment Is Expected to Grow at the Fastest Rate?

On the basis of product & services, the DNA synthesis market is bifurcated into product and services. the product segment is expected to register the highest CAGR during the forecast period owing to the rising adoption of advanced synthesis platforms, increasing demand for reagents, kits, and consumables, and continuous technological advancements enabling scalable and automated DNA production.

On the basis of type, the DNA synthesis industry is segregated into oligonucleotide synthesis and gene synthesis. the gene synthesis segment is expected to register the highest CAGR during the forecast period. This is attributed to the increasing demand for long and complex DNA constructs in synthetic biology, gene therapy, vaccine development, and advanced genetic engineering applications.

On the basis of application, the DNA synthesis industry is categorized into diagnostics, therapeutics, and research & development. therapeutics is expected to register the highest CAGR during the DNA synthesis market forecast period. This is attributed to the growing adoption of gene-based therapies, personalized medicine approaches, and increasing clinical pipeline activities focused on treating genetic and rare diseases.

On the basis of end user, the DNA synthesis market is categorized into pharmaceutical & biotechnology companies, diagnostic companies, academic & research institutes, and others. Academic & research institutes are expected to register the highest CAGR during the DNA synthesis market analysis period. This is attributed to rising government and private funding for genomics research, increasing collaborations with biotech firms, and expanding adoption of advanced molecular biology techniques in educational and research settings.

Competitive Landscape

Who Are the Key Players in the DNA Synthesis market and What Are Their Strategies?

Key players in the DNA Synthesis market include Danaher Corporation, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Twist Bioscience, GenScript Biotech Corporation, Merck KGaA, Bioneer Corporation, Telesis Bio, Azenta Inc., and Ajinomoto Bio-Pharma.

• In May 2024, Integrated DNA Technologies expanded its synthetic biology capabilities by opening a 25,000-square-foot facility in Coralville. This development effectively doubled the company’s operational footprint in the synthetic biology segment, representing a major scale-up of its production and innovation capacity.

Technology, AI & Innovation (Future-Facing)

• AI-driven DNA design and optimization: Advanced machine learning algorithms are being used to design error-free DNA sequences, optimize codon usage, and predict synthesis success rates, significantly reducing trial-and-error in laboratories.
• Automated high-throughput synthesis platforms: Companies like Twist Bioscience and Telesis Bio are developing fully automated platforms capable of producing thousands of DNA constructs simultaneously with high precision and speed
• Next-generation enzymatic DNA synthesis: Emerging enzymatic synthesis technologies are replacing traditional chemical methods, enabling faster, more environmentally friendly, and more accurate DNA production.
• Integration with cloud-based bioinformatics tools: DNA synthesis workflows are increasingly connected with cloud platforms for sequence design, simulation, storage, and collaboration, enhancing scalability and global accessibility.
• Microfluidics and lab-on-a-chip innovations: Miniaturized systems are enabling precise control over reactions, reducing reagent consumption, and allowing portable, scalable DNA synthesis solutions..
• Digital biofoundries and end-to-end automation: Companies such as GenScript Biotech Corporation are building integrated biofoundries that combine robotics, AI, and data analytics for seamless design-to-build DNA workflows.
• On-demand and decentralized DNA manufacturing: Portable synthesis systems are emerging, enabling on-site DNA production for applications in healthcare, defense, and remote research environments.
• Advancements in long DNA and gene synthesis: Innovations are enabling the synthesis of longer and more complex DNA sequences, supporting synthetic genomes and advanced genetic engineering projects.
• Convergence with mRNA and cell/gene therapy manufacturing: DNA synthesis is increasingly integrated into broader biologics pipelines, supporting next-generation therapeutics and personalized medicine initiatives led by firms like Thermo Fisher Scientific Inc.

Regional Insights 

Which Region Dominates the Global DNA Synthesis market and What Drives Its Leadership?

Region-wise, North America dominated the market share in 2025. This was attributed to the strong presence of leading biotechnology and pharmaceutical companies, advanced research infrastructure, high adoption of gene synthesis technologies, and significant investment in genomics and precision medicine. However, Asia-Pacific is expected to register the highest CAGR during the forecast period. This is attributed to the rapid expansion of biotechnology research capabilities, increasing government support for life sciences innovation, growing outsourcing activities from global companies, and the rising number of academic and research institutions across emerging economies.

What Role Does Government Policies Play in DNA Synthesis market?

• Funding and grants for life sciences research: Public funding programs support genomics, synthetic biology, and biotechnology R&D, increasing demand for DNA synthesis in academic and commercial research.
• Regulatory frameworks and compliance standards: Governments establish biosafety, biosecurity, and ethical guidelines for DNA synthesis, ensuring safe use while maintaining industry credibility and trust..
• Support for innovation and commercialization: Policies that encourage technology transfer, startup incubation, and public–private partnerships help accelerate the development and adoption of advanced DNA synthesis technologies.
• Intellectual property (IP) protection: Strong patent systems incentivize companies like Thermo Fisher Scientific Inc. and GenScript Biotech Corporation to invest in novel synthesis methods and proprietary platforms.
• Quality and manufacturing standards: Regulations governing GMP (Good Manufacturing Practices) ensure high-quality DNA products, especially for clinical and therapeutic applications.
• Biosecurity and sequence screening requirements: Governments may mandate screening of synthetic DNA orders to prevent misuse (e.g., harmful pathogens), influencing operational processes and costs..
• Trade policies and cross-border regulations: Import/export rules, tariffs, and international compliance standards impact global supply chains and distribution of DNA synthesis products.
• Incentives for local manufacturing and biotech hubs: Tax benefits, subsidies, and infrastructure development programs promote domestic production and strengthen regional biotech ecosystems.
• Ethical guidelines and data governance: Policies addressing genetic data privacy, human gene editing, and ethical use of biotechnology shape market adoption and public acceptance.
• Pandemic preparedness and public health initiatives: Government-driven programs for vaccine development and rapid response capabilities (e.g., mRNA platforms) significantly boost demand for DNA synthesis services.

Top Player’s Company Profiles

• Danaher Corporation
• Eurofins Scientific SE
• Thermo Fisher Scientific Inc.
• Twist Bioscience
• GenScript Biotech Corporation
• Merck KGaA
• Bioneer Corporation
• Telesis Bio
• Azenta Inc
• Ajinomoto Bio-Pharma.

DNA Synthesis Key Market Trends

• Shift toward enzymatic DNA synthesis technologies: New enzymatic methods are gaining traction over traditional chemical synthesis due to higher accuracy, faster turnaround times, and reduced environmental impact.
• Rising adoption of automation and high-throughput platforms: Companies like Twist Bioscience and Telesis Bio are leveraging automation to scale production, improve efficiency, and lower costs.
• Growing demand from mRNA therapeutics and vaccines: The expansion of mRNA-based drugs and vaccines is significantly increasing the need for high-quality synthetic DNA as a starting material.
• Integration of AI and bioinformatics tools: AI-driven platforms are being used to design, optimize, and validate DNA sequences, enhancing precision and reducing development timelines..
• Expansion of synthetic biology and gene editing applications: Increasing use of technologies like CRISPR across healthcare, agriculture, and industrial biotech is driving demand for custom DNA constructs.
• Emergence of long and complex DNA synthesis capabilities: Advances in synthesis technologies are enabling the production of longer gene sequences and even synthetic genomes, opening new possibilities in advanced research and therapeutics.

DNA Synthesis market AMR Analysis

As per AMR analysis, the DNA synthesis market is witnessing strong growth driven by the rapid expansion of synthetic biology, increasing demand for gene-based research, and the rising adoption of DNA synthesis across pharmaceuticals, biotechnology, agriculture, and industrial applications. DNA synthesis enables the accurate and scalable production of custom DNA sequences, which are essential for applications such as drug discovery, vaccine development, gene therapy, and genetic engineering. The growing focus on personalized medicine, along with the increasing use of mRNA-based therapeutics, is further accelerating demand. In addition, continuous technological advancements such as automation, high-throughput synthesis platforms, and AI-driven sequence design are improving efficiency, reducing costs, and enhancing the overall quality of synthesized DNA.

However, the market faces certain restraints, including the high cost associated with advanced DNA synthesis technologies and infrastructure, as well as technical challenges related to error rates in long-sequence synthesis. Regulatory and ethical concerns surrounding genetic manipulation and synthetic biology can also limit market growth. Additionally, the need for skilled professionals, complex validation processes, and concerns related to biosecurity and misuse of synthetic DNA may hinder broader adoption, particularly in emerging markets.

North America is expected to dominate the market owing to its well-established biotechnology and pharmaceutical ecosystem, strong presence of leading companies such as Thermo Fisher Scientific Inc., Danaher Corporation, and Twist Bioscience, and significant investments in research and development. The region also benefits from advanced healthcare infrastructure, supportive government funding, and early adoption of cutting-edge technologies. Meanwhile, Asia-Pacific is expected to witness the fastest growth due to increasing investments in biotechnology, expanding research capabilities, and the rapid growth of pharmaceutical and academic sectors in countries such as China, India, and Japan.

Nevertheless, several growth opportunities are emerging, including the development of enzymatic DNA synthesis technologies, integration of AI and machine learning for sequence optimization, and the rise of automated biofoundries. Increasing demand for synthetic DNA in emerging areas such as cell and gene therapy, CRISPR-based applications, and DNA data storage is further expected to create new revenue streams. Moreover, strategic collaborations and partnerships among key players such as GenScript Biotech Corporation, Merck KGaA, and Eurofins Scientific SE are likely to drive innovation, enhance production capabilities, and expand the global adoption of DNA synthesis solutions.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the DNA synthesis market analysis from 2025 to 2035 to identify the prevailing DNA synthesis market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the DNA synthesis market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global DNA synthesis market trends, key players, market segments, application areas, and market growth strategies.

DNA Synthesis Market Report Highlights

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter s five forces analysis
3.3.1. Moderate bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. High intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rising Demand for Genomics and Precision Medicine

3.4.1.2. Growth in Synthetic Biology and Biopharmaceutical Innovation

3.4.1.3. Technological Advancements in Automation and High-Throughput Synthesis

3.4.2. Restraints

3.4.2.1. High Cost and Technical Complexity of Long-Sequence DNA Synthesis

3.4.2.2. Ethical, Regulatory, and Biosecurity Concerns

3.4.3. Opportunities

3.4.3.1. Expansion of Gene and Cell Therapy Applications

CHAPTER 4: DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE
4.1. Overview

4.1.1. Market size and forecast

4.2. Product
4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.2.4. Product DNA Synthesis Market by Type
4.2.4.1. Instruments Market size and forecast, by region

4.2.4.2. Reagents and Consumables Market size and forecast, by region

4.3. Services
4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

CHAPTER 5: DNA SYNTHESIS MARKET, BY TYPE
5.1. Overview

5.1.1. Market size and forecast

5.2. Oligonucleotide Synthesis
5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Gene Synthesis
5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

CHAPTER 6: DNA SYNTHESIS MARKET, BY APPLICATION
6.1. Overview

6.1.1. Market size and forecast

6.2. Diagnostics
6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Therapeutics
6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Research and Development
6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

CHAPTER 7: DNA SYNTHESIS MARKET, BY END USER
7.1. Overview

7.1.1. Market size and forecast

7.2. Pharmaceutical and Biotechnology Companies
7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Diagnostic Companies
7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Academic and Research Institutes
7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

7.5. Others
7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by region

7.5.3. Market share analysis by country

CHAPTER 8: DNA SYNTHESIS MARKET, BY REGION
8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America
8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Product and Service
8.2.2.1. North America Product DNA Synthesis Market by Type

8.2.3. Market size and forecast, by Type

8.2.4. Market size and forecast, by Application

8.2.5. Market size and forecast, by End User

8.2.6. Market size and forecast, by country
8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Product and Service
8.2.6.1.2. Market size and forecast, by Type
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by End User

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Product and Service
8.2.6.2.2. Market size and forecast, by Type
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by End User

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Product and Service
8.2.6.3.2. Market size and forecast, by Type
8.2.6.3.3. Market size and forecast, by Application
8.2.6.3.4. Market size and forecast, by End User

8.3. Europe
8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Product and Service
8.3.2.1. Europe Product DNA Synthesis Market by Type

8.3.3. Market size and forecast, by Type

8.3.4. Market size and forecast, by Application

8.3.5. Market size and forecast, by End User

8.3.6. Market size and forecast, by country
8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Product and Service
8.3.6.1.2. Market size and forecast, by Type
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by End User

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Product and Service
8.3.6.2.2. Market size and forecast, by Type
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by End User

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Product and Service
8.3.6.3.2. Market size and forecast, by Type
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by End User

8.3.6.4. Italy

8.3.6.4.1. Market size and forecast, by Product and Service
8.3.6.4.2. Market size and forecast, by Type
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by End User

8.3.6.5. Spain

8.3.6.5.1. Market size and forecast, by Product and Service
8.3.6.5.2. Market size and forecast, by Type
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by End User

8.3.6.6. Rest of Europe

8.3.6.6.1. Market size and forecast, by Product and Service
8.3.6.6.2. Market size and forecast, by Type
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by End User

8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Product and Service
8.4.2.1. Asia-Pacific Product DNA Synthesis Market by Type

8.4.3. Market size and forecast, by Type

8.4.4. Market size and forecast, by Application

8.4.5. Market size and forecast, by End User

8.4.6. Market size and forecast, by country
8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Product and Service
8.4.6.1.2. Market size and forecast, by Type
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by End User

8.4.6.2. China

8.4.6.2.1. Market size and forecast, by Product and Service
8.4.6.2.2. Market size and forecast, by Type
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by End User

8.4.6.3. India

8.4.6.3.1. Market size and forecast, by Product and Service
8.4.6.3.2. Market size and forecast, by Type
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by End User

8.4.6.4. Australia

8.4.6.4.1. Market size and forecast, by Product and Service
8.4.6.4.2. Market size and forecast, by Type
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by End User

8.4.6.5. South Korea

8.4.6.5.1. Market size and forecast, by Product and Service
8.4.6.5.2. Market size and forecast, by Type
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by End User

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Market size and forecast, by Product and Service
8.4.6.6.2. Market size and forecast, by Type
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by End User

8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Product and Service
8.5.2.1. LAMEA Product DNA Synthesis Market by Type

8.5.3. Market size and forecast, by Type

8.5.4. Market size and forecast, by Application

8.5.5. Market size and forecast, by End User

8.5.6. Market size and forecast, by country
8.5.6.1. Brazil

8.5.6.1.1. Market size and forecast, by Product and Service
8.5.6.1.2. Market size and forecast, by Type
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by End User

8.5.6.2. Saudi Arabia

8.5.6.2.1. Market size and forecast, by Product and Service
8.5.6.2.2. Market size and forecast, by Type
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by End User

8.5.6.3. South Africa

8.5.6.3.1. Market size and forecast, by Product and Service
8.5.6.3.2. Market size and forecast, by Type
8.5.6.3.3. Market size and forecast, by Application
8.5.6.3.4. Market size and forecast, by End User

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Market size and forecast, by Product and Service
8.5.6.4.2. Market size and forecast, by Type
8.5.6.4.3. Market size and forecast, by Application
8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction

9.2. Top winning strategies

9.3. Product mapping of top 10 player

9.4. Competitive dashboard

9.5. Competitive heatmap

9.6. Top player positioning, 2025

CHAPTER 10: COMPANY PROFILES
10.1. Bioneer Corporation
10.1.1. Company overview

10.1.2. Key executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

10.2. Danaher Corporation
10.2.1. Company overview

10.2.2. Key executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.2.6. Business performance

10.2.7. Key strategic moves and developments

10.3. Eurofins Scientific SE
10.3.1. Company overview

10.3.2. Key executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.3.6. Business performance

10.4. Thermo Fisher Scientific Inc.
10.4.1. Company overview

10.4.2. Key executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.6. Business performance

10.5. Twist Bioscience
10.5.1. Company overview

10.5.2. Key executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.5.6. Business performance

10.6. GenScript Biotech Corporation
10.6.1. Company overview

10.6.2. Key executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.6.6. Business performance

10.7. Telesis Bio
10.7.1. Company overview

10.7.2. Key executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.7.6. Business performance

10.8. Azenta Inc.
10.8.1. Company overview

10.8.2. Key executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.8.6. Business performance

10.9. Ajinomoto Bio-Pharma
10.9.1. Company overview

10.9.2. Key executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Business performance

10.10. Merck KGaA
10.10.1. Company overview

10.10.2. Key executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfolio

10.10.6. Business performance

LIST OF TABLES

TABLE 01. GLOBAL DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 02. DNA SYNTHESIS MARKET FOR PRODUCT, BY REGION, 2025-2035 ($MILLION)
TABLE 03. GLOBAL PRODUCT DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 04. DNA SYNTHESIS MARKET FOR INSTRUMENTS, BY REGION, 2025-2035 ($MILLION)
TABLE 05. DNA SYNTHESIS MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2025-2035 ($MILLION)
TABLE 06. DNA SYNTHESIS MARKET FOR SERVICES, BY REGION, 2025-2035 ($MILLION)
TABLE 07. GLOBAL DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 08. DNA SYNTHESIS MARKET FOR OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2025-2035 ($MILLION)
TABLE 09. DNA SYNTHESIS MARKET FOR GENE SYNTHESIS, BY REGION, 2025-2035 ($MILLION)
TABLE 10. GLOBAL DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 11. DNA SYNTHESIS MARKET FOR DIAGNOSTICS, BY REGION, 2025-2035 ($MILLION)
TABLE 12. DNA SYNTHESIS MARKET FOR THERAPEUTICS, BY REGION, 2025-2035 ($MILLION)
TABLE 13. DNA SYNTHESIS MARKET FOR RESEARCH AND DEVELOPMENT, BY REGION, 2025-2035 ($MILLION)
TABLE 14. GLOBAL DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 15. DNA SYNTHESIS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2035 ($MILLION)
TABLE 16. DNA SYNTHESIS MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2025-2035 ($MILLION)
TABLE 17. DNA SYNTHESIS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2035 ($MILLION)
TABLE 18. DNA SYNTHESIS MARKET FOR OTHERS, BY REGION, 2025-2035 ($MILLION)
TABLE 19. DNA SYNTHESIS MARKET, BY REGION, 2025-2035 ($MILLION)
TABLE 20. NORTH AMERICA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 21. NORTH AMERICA PRODUCT DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 22. NORTH AMERICA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 23. NORTH AMERICA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 24. NORTH AMERICA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 25. NORTH AMERICA DNA SYNTHESIS MARKET, BY COUNTRY, 2025-2035 ($MILLION)
TABLE 26. U.S. DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 27. U.S. DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 28. U.S. DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 29. U.S. DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 30. CANADA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 31. CANADA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 32. CANADA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 33. CANADA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 34. MEXICO DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 35. MEXICO DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 36. MEXICO DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 37. MEXICO DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 38. EUROPE DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 39. EUROPE PRODUCT DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 40. EUROPE DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 41. EUROPE DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 42. EUROPE DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 43. EUROPE DNA SYNTHESIS MARKET, BY COUNTRY, 2025-2035 ($MILLION)
TABLE 44. GERMANY DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 45. GERMANY DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 46. GERMANY DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 47. GERMANY DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 48. FRANCE DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 49. FRANCE DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 50. FRANCE DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 51. FRANCE DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 52. UK DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 53. UK DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 54. UK DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 55. UK DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 56. ITALY DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 57. ITALY DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 58. ITALY DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 59. ITALY DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 60. SPAIN DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 61. SPAIN DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 62. SPAIN DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 63. SPAIN DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 64. REST OF EUROPE DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 65. REST OF EUROPE DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 66. REST OF EUROPE DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 67. REST OF EUROPE DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 68. ASIA-PACIFIC DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 69. ASIA-PACIFIC PRODUCT DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 70. ASIA-PACIFIC DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 71. ASIA-PACIFIC DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 72. ASIA-PACIFIC DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 73. ASIA-PACIFIC DNA SYNTHESIS MARKET, BY COUNTRY, 2025-2035 ($MILLION)
TABLE 74. JAPAN DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 75. JAPAN DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 76. JAPAN DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 77. JAPAN DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 78. CHINA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 79. CHINA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 80. CHINA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 81. CHINA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 82. INDIA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 83. INDIA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 84. INDIA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 85. INDIA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 86. AUSTRALIA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 87. AUSTRALIA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 88. AUSTRALIA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 89. AUSTRALIA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 90. SOUTH KOREA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 91. SOUTH KOREA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 92. SOUTH KOREA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 93. SOUTH KOREA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 98. LAMEA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 99. LAMEA PRODUCT DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 100. LAMEA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 101. LAMEA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 102. LAMEA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 103. LAMEA DNA SYNTHESIS MARKET, BY COUNTRY, 2025-2035 ($MILLION)
TABLE 104. BRAZIL DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 105. BRAZIL DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 106. BRAZIL DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 107. BRAZIL DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 108. SAUDI ARABIA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 109. SAUDI ARABIA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 110. SAUDI ARABIA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 111. SAUDI ARABIA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 112. SOUTH AFRICA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 113. SOUTH AFRICA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 114. SOUTH AFRICA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 115. SOUTH AFRICA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 116. REST OF LAMEA DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025-2035 ($MILLION)
TABLE 117. REST OF LAMEA DNA SYNTHESIS MARKET, BY TYPE, 2025-2035 ($MILLION)
TABLE 118. REST OF LAMEA DNA SYNTHESIS MARKET, BY APPLICATION, 2025-2035 ($MILLION)
TABLE 119. REST OF LAMEA DNA SYNTHESIS MARKET, BY END USER, 2025-2035 ($MILLION)
TABLE 120. BIONEER CORPORATION: KEY EXECUTIVES
TABLE 121. BIONEER CORPORATION: COMPANY SNAPSHOT
TABLE 122. BIONEER CORPORATION: PRODUCT SEGMENTS
TABLE 123. BIONEER CORPORATION: PRODUCT PORTFOLIO
TABLE 124. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 125. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 126. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 127. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 128. DANAHER CORPORATION: KEY STRATERGIES
TABLE 129. EUROFINS SCIENTIFIC SE: KEY EXECUTIVES
TABLE 130. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT
TABLE 131. EUROFINS SCIENTIFIC SE: PRODUCT SEGMENTS
TABLE 132. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO
TABLE 133. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 134. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 135. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 136. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 137. TWIST BIOSCIENCE: KEY EXECUTIVES
TABLE 138. TWIST BIOSCIENCE: COMPANY SNAPSHOT
TABLE 139. TWIST BIOSCIENCE: PRODUCT SEGMENTS
TABLE 140. TWIST BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 141. GENSCRIPT BIOTECH CORPORATION: KEY EXECUTIVES
TABLE 142. GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT
TABLE 143. GENSCRIPT BIOTECH CORPORATION: PRODUCT SEGMENTS
TABLE 144. GENSCRIPT BIOTECH CORPORATION: PRODUCT PORTFOLIO
TABLE 145. TELESIS BIO: KEY EXECUTIVES
TABLE 146. TELESIS BIO: COMPANY SNAPSHOT
TABLE 147. TELESIS BIO: PRODUCT SEGMENTS
TABLE 148. TELESIS BIO: PRODUCT PORTFOLIO
TABLE 149. AZENTA INC.: KEY EXECUTIVES
TABLE 150. AZENTA INC.: COMPANY SNAPSHOT
TABLE 151. AZENTA INC.: PRODUCT SEGMENTS
TABLE 152. AZENTA INC.: PRODUCT PORTFOLIO
TABLE 153. AJINOMOTO BIO-PHARMA: KEY EXECUTIVES
TABLE 154. AJINOMOTO BIO-PHARMA: COMPANY SNAPSHOT
TABLE 155. AJINOMOTO BIO-PHARMA: PRODUCT SEGMENTS
TABLE 156. AJINOMOTO BIO-PHARMA: PRODUCT PORTFOLIO
TABLE 157. MERCK KGAA: KEY EXECUTIVES
TABLE 158. MERCK KGAA: COMPANY SNAPSHOT
TABLE 159. MERCK KGAA: PRODUCT SEGMENTS
TABLE 160. MERCK KGAA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. DNA SYNTHESIS MARKET, 2025-2035
FIGURE 02. SEGMENTATION OF DNA SYNTHESIS MARKET,2025-2035
FIGURE 03. TOP IMPACTING FACTORS IN DNA SYNTHESIS MARKET (2025 TO 2035)
FIGURE 04. TOP INVESTMENT POCKETS IN DNA SYNTHESIS MARKET (2026-2035)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. HIGH INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL DNA SYNTHESIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. DNA SYNTHESIS MARKET, BY PRODUCT AND SERVICE, 2025 AND 2035(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY 2025 AND 2035(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR SERVICES, BY COUNTRY 2025 AND 2035(%)
FIGURE 14. DNA SYNTHESIS MARKET, BY TYPE, 2025 AND 2035(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY 2025 AND 2035(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR GENE SYNTHESIS, BY COUNTRY 2025 AND 2035(%)
FIGURE 17. DNA SYNTHESIS MARKET, BY APPLICATION, 2025 AND 2035(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR DIAGNOSTICS, BY COUNTRY 2025 AND 2035(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR THERAPEUTICS, BY COUNTRY 2025 AND 2035(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY 2025 AND 2035(%)
FIGURE 21. DNA SYNTHESIS MARKET, BY END USER, 2025 AND 2035(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2025 AND 2035(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY 2025 AND 2035(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY 2025 AND 2035(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF DNA SYNTHESIS MARKET FOR OTHERS, BY COUNTRY 2025 AND 2035(%)
FIGURE 26. DNA SYNTHESIS MARKET BY REGION, 2025 AND 2035(%)
FIGURE 27. U.S. DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 28. CANADA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 29. MEXICO DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 30. GERMANY DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 31. FRANCE DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 32. UK DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 33. ITALY DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 34. SPAIN DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 35. REST OF EUROPE DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 36. JAPAN DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 37. CHINA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 38. INDIA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 39. AUSTRALIA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 40. SOUTH KOREA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 41. REST OF ASIA-PACIFIC DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 42. BRAZIL DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 43. SAUDI ARABIA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 44. SOUTH AFRICA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 45. REST OF LAMEA DNA SYNTHESIS MARKET, 2025-2035 ($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2024)
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2024)
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2024)
FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50. COMPETITIVE DASHBOARD
FIGURE 51. COMPETITIVE HEATMAP: DNA SYNTHESIS MARKET
FIGURE 52. TOP PLAYER POSITIONING, 2025
FIGURE 53. BIONEER CORPORATION: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 54. EUROFINS SCIENTIFIC SE: NET REVENUE, 2023-2025 ($MILLION)
FIGURE 55. EUROFINS SCIENTIFIC SE: REVENUE SHARE BY SEGMENT, 2025 (%)
FIGURE 56. EUROFINS SCIENTIFIC SE: REVENUE SHARE BY REGION, 2025 (%)
FIGURE 57. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2023-2025 ($MILLION)
FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2025 (%)
FIGURE 59. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2025 (%)
FIGURE 60. TWIST BIOSCIENCE: NET REVENUE, 2023-2025 ($MILLION)
FIGURE 61. TWIST BIOSCIENCE: REVENUE SHARE BY REGION, 2025 (%)
FIGURE 62. TWIST BIOSCIENCE: REVENUE SHARE BY SEGMENT, 2025 (%)
FIGURE 63. GENSCRIPT BIOTECH CORPORATION: NET REVENUE, 2023-2025 ($MILLION)
FIGURE 64. GENSCRIPT BIOTECH CORPORATION: REVENUE SHARE BY SEGMENT, 2025 (%)
FIGURE 65. GENSCRIPT BIOTECH CORPORATION: REVENUE SHARE BY REGION, 2025 (%)
FIGURE 66. TELESIS BIO: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 67. TELESIS BIO: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 68. AZENTA INC.: NET SALES, 2023-2025 ($MILLION)
FIGURE 69. AZENTA INC.: REVENUE SHARE BY SEGMENT, 2025 (%)
FIGURE 70. AZENTA INC.: REVENUE SHARE BY REGION, 2025 (%)
FIGURE 71. AJINOMOTO BIO-PHARMA: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 72. AJINOMOTO BIO-PHARMA: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 73. MERCK KGAA: NET SALES, 2023-2025 ($MILLION)
FIGURE 74. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2025 (%)
FIGURE 75. MERCK KGAA: REVENUE SHARE BY REGION, 2025 (%)

---

---